Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J M Lewis

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
BMJ (Clinical Research Ed.)|February 19, 2009
Unnecessary universal BCG in UK. Efficacy of BCG: three quarters full or one quarter empty?David J M Lewis
Journal of Immunology Research|September 18, 2015
Application of "Systems Vaccinology" to Evaluate Inflammation and Reactogenicity of Adjuvanted Preventative VaccinesDavid J M Lewis, Mark P Lythgoe
Methods in Molecular Medicine|September 6, 2003
Stimulation of mucosal immunityDavid J M Lewis, Christopher M M Hayward
Vaccine|May 24, 2003
Novel human vaccine strategies and the 5th Framework Programme: pushing the envelopeAldo Tagliabue, Maria Paola Cesaroni, David J M Lewis
Nature Reviews. Urology|September 18, 2013
BCG immunotherapy for bladder cancer--the effects of substrain differencesChristine Gan, Hugh Mostafid, Muhammad Shamim Khan, et al.
Vaccine|April 8, 2016
Anticipating policy considerations for a future HIV vaccine: a preliminary studyEmmanuel Ato Williams, David J M Lewis, Sylvie Bertholet, et al.
Nature Reviews. Urology|May 20, 2015
Corrigendum: BCG immunotherapy for bladder cancer--the effects of substrain differencesChristine Gan, Hugh Mostafid, Muhammad Shamim Khan, et al.
Current Opinion in Immunology|February 25, 2014
Challenges and responses in human vaccine developmentStefan H E Kaufmann, M Juliana McElrath, David J M Lewis, et al.
Plos One|March 23, 2012
Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteersZhiming Huo, Sara L Bissett, Raphaela Giemza, et al.
Biologicals : Journal of the International Association of Biological Standardization|December 1, 2012
Potential use of inflammation and early immunological event biomarkers in assessing vaccine safetyBéatris Mastelic, David J M Lewis, Hana Golding, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
BMJ (Clinical Research Ed.)|February 19, 2009
Unnecessary universal BCG in UK. Efficacy of BCG: three quarters full or one quarter empty?David J M Lewis
Journal of Immunology Research|September 18, 2015
Application of "Systems Vaccinology" to Evaluate Inflammation and Reactogenicity of Adjuvanted Preventative VaccinesDavid J M Lewis, Mark P Lythgoe
Methods in Molecular Medicine|September 6, 2003
Stimulation of mucosal immunityDavid J M Lewis, Christopher M M Hayward
Vaccine|May 24, 2003
Novel human vaccine strategies and the 5th Framework Programme: pushing the envelopeAldo Tagliabue, Maria Paola Cesaroni, David J M Lewis
Nature Reviews. Urology|September 18, 2013
BCG immunotherapy for bladder cancer--the effects of substrain differencesChristine Gan, Hugh Mostafid, Muhammad Shamim Khan, et al.
Vaccine|April 8, 2016
Anticipating policy considerations for a future HIV vaccine: a preliminary studyEmmanuel Ato Williams, David J M Lewis, Sylvie Bertholet, et al.
Nature Reviews. Urology|May 20, 2015
Corrigendum: BCG immunotherapy for bladder cancer--the effects of substrain differencesChristine Gan, Hugh Mostafid, Muhammad Shamim Khan, et al.
Current Opinion in Immunology|February 25, 2014
Challenges and responses in human vaccine developmentStefan H E Kaufmann, M Juliana McElrath, David J M Lewis, et al.
Plos One|March 23, 2012
Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteersZhiming Huo, Sara L Bissett, Raphaela Giemza, et al.
Biologicals : Journal of the International Association of Biological Standardization|December 1, 2012
Potential use of inflammation and early immunological event biomarkers in assessing vaccine safetyBéatris Mastelic, David J M Lewis, Hana Golding, et al.
Pageof 5